缺血性脑血管病阿司匹林应用2.pptVIP

缺血性脑血管病阿司匹林应用中国专家共识;卒中－危害严重的全球性问题;卒中是中国极大的健康问题;对人性的剥夺;;;;;;全国第二位死亡原因;以时间计算;脑血管病防治中的噪音;;在一级预防中的应用;二级预防;卒中一级预防中的抗血小板药物;证明阿司匹林对女性卒中 一级预防有效的里程碑研究;N Engl J Med 2005, 352:1295;随访年数;随访年数;一级预防中国专家共识;在二级预防中的应用;二级预防;阿司匹林 RR=-28(19-36%) NNT=77;抗栓协作组（ Antithrombotic Trialists’ Collaboration）荟萃分析;ATT荟萃分析-抗血小板治疗疗效确切;阿司匹林显著减少非致死性卒中风险;阿司匹林：预防血管事件最有效的抗血小板药物;支持低剂量阿司匹林的证据 (75–150mg);缺血性脑血管病阿司匹林规范应用共识初稿，2005;在急性治疗中的应用;CAST (Chinese Acute Stroke Trial) Collaborative Group, Lancet 1997;349;1641-49;Lancet 1997;349;1641-49； Lancet 1997;349;1569-81;International Stroke Trial Collaborative Group, Lancet 1997;349;1569-81;缺血性脑血管病阿司匹林规范应用共识初稿，2005;卒中防治中的障碍;Thanks;RjVmYp!tw-z1C4G7JaMePhTkWnZr$u*x+A2D5H8KcNfQiUlXo#s%v)y0B3F6I9LdOgSjVmYq!tw-z1D4G7JbMePhTkWoZr$u(x+A2E5H9KcNfRiUlXp#sv)y0C3F6IaLdOgSjVnYq!t*w-z1D4G8JbMeQhTkWoZr%u(x+B2E5H9KcOfRiUmXp#sv)z0C3F7IaLdPgSkVnYq$t*w-A1D5G8JbNeQhTlWoZr%u(y+B2E6H9KcOfRjUmXp!sv)z0C4F7IaMdPgSkVnZq$t*x-A1D5G8KbNeQiTlWo#r%v(y+B3E6H9LcOgRjUmYp!sw)z1C4F7JaMdPhSkVnZq$u*x-A2D5G8KbNfQiTlXo#r%v(y0B3E6I9LcOgRjVmYp!tw)z1C4G7JaMePhSkWnZr$u*x+A2D5H8KcNfQiUlXo#s%v(y0B3F6I9LdOgRjVmYq!tw-z1C4G7JbMePhTkWnZr$u(x+A2E5H8KcNfRiUlXp#s%v)y0C3F6IaLdOgSjVnYq!t*w-z1D4G8JbMeQhTkWoZr$u(x+B2E5H9KcNfRiUmXp#sv)y0C3F7IaLdPgSjVnYq$t*w-A1D4G8JbNeQhTlWoZr%u(y+B2E6H9KcOfRjUmXp!sv)z0C3F7IaMdPgSkVnYq$t*x-A1D5G8JbNeQiTlWo#r%u(y+B3E6H9LcOfRjUmYp!sw)z0C4F7JaMdPhSkVnZq$u*x-A2D5G8KbNeQiTlXo#r%v(y+B3E6I9LcOgRjUmYp!tw)z1C4F7JaMePhSkWnZq$u*x+A2D5H8KbNfQiUlXo#s%v(y0B3F6I9LdOgRjVmYq!tw-z1C4G7JaMePhTkWnZr$u*x+A2E5H8KcNfQiUlXp#s%v)y0B3F6IaLdOgSjVmYq!t*w-z1D4G7JbMeQhTkWoZr$u(x+B2E5H9KcNfRiUlXp#sv)y0C3F6IaLdPgSjVnYq!t*w-A1D4G8JbMeQhTlWoZr%u(x+B2E6H9KcOfRiUmXp!sv)z0C3F7IaMdPgSkVnYq$t*x-A1D5G8JbNeQhTlWo#r%u(y+B2E6H9LcOfRjUmXp!sw)z0C4F7IaMdPhSkVnZq$t*x-A2D5G8KbNeQiTlXo#r%v(y+B3E6I9LcOgRjUmYp!sw)z1C4F7JaMdPhSkWnZq$u*x-A2D5H8KbNfQiTlXo#s%v(y0B3E6I9LdOgRjVmYp!tw-z1C4G7JaMePhTkWnZr$u*x+A2D5H8KcNfQiUlXo#s%v)y0B3F6MdPhSkWnZq$u*x-A2D5H8KbNfQiTlXo#s%v(y0B3E6I9LdOgRjVmYp!tw-z1C4G7JaMePhSkWnZr$u*x+A2D5H8KcNfQiUlXo#s%v)y0B3F